Dr. Mansoor Raza Mirza has served as Acrivon's Chief Medical Officer since April 2025. A globally recognized gynecologic-oncology key opinion leader, he previously served as chief oncologist at Copenhagen University National Medical Center (Rigshospitalet) in Denmark from 2009 to 2025 and as medical director of the Nordic Society of Gynecologic Oncology Clinical Trial Unit. He was lead investigator of the first global Phase 3 PARP-inhibitor trial in ovarian cancer (NOVA) and the dostarlimab first-line endometrial-cancer trial (RUBY), and has authored more than 200 peer-reviewed publications. He is a past chair of the European Network of Gynecological Oncological Trial Group and vice-president of the European Society of Gynecological Oncology, and serves on the boards of Karyopharm Therapeutics and Sera Prognostics. Dr. Mirza earned his medical degree and diplomas in surgery and clinical oncology from the Pirogov Moscow State Medical Institute and completed further oncology training at the University of Southern Denmark.